You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)擬折讓8.8%配股 料淨集資23.6億元
阿思達克 09-12 08:35
信達生物(01801.HK)公布,計劃配售6,800萬股,佔公司擴大後股本約4.22%,每股配售價為34.92元,較公司昨日(11日)收市價38.3元折讓約8.83%。 公司預期配售事項淨集資約23.57億元,擬將約60%用於加速全球管線的多項優先臨床前及臨床計劃的研發,包括但不限於開展多區域臨床試驗,以及建設全球基礎設施及設備;約30%用於開發、營銷及商業化IBI362(瑪仕度(月太)),一種治療糖尿病及肥胖的GLP-1R/GCGR雙激動劑及潛在臨床階段最佳候選藥物;約10%作一般及企業用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account